A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

• Status: Terminated
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to patients with stage IIIB and IV non-small cell lung cancer. This study will also evaluate the preliminary efficacy (Phase II component) of bexarotene oral capsules in combination with the weekly Taxol® schedule and carboplatin in these patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborators: Bristol-Myers Squibb; Ligand Pharmaceuticals
• Treatments: Bexarotene; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• unresectable stage IIIB or IV NSCLC

• adequate bone marrow, hepatic, thyroid and renal function

Exclusion Criteria:

• peripheral neuropathy >= grade 2

• gastrointestinal abnormalities

• known hypersensitivity to retinoids